#ST Pharm 237690 | Stock channels

ST Pharm237690

₩89,800-3.23%Close Oct 22

This is the start of #ST Pharm

Talk about ST Pharm here. Pull up price, chart, news and filings just for you from the message box, or mention @InverseOneBot to get an answer everyone can see.

InverseOne BotBOTOnly visible to you

Welcome to the ST Pharm channel. Here's the latest data.

에스티팜 237690

Close as of Oct 22

₩89,800-3.23%

Low ₩82,10052-week rangeHigh ₩172,100

At a glance: 9% of the 52-week range, estimated net outflow, lending balance growing, filing check: No hurdle.

Disappears when you reload.

에스티팜 237690

Close as of Oct 22

₩89,800-3.23%

Low ₩82,10052-week rangeHigh ₩172,100

5 sessions

+7.2%

20 sessions

-3.1%

60 sessions

-23.8%

Volume

0.7x average

Price

Apr 10 ~ Oct 22

₩89,800-37.33%

Low ₩83,800High ₩168,700

Money flow

as of Oct 22

Strong outflow index-₩162.8M

Net flow, Outflow

Market flow rank: Outflow #51 of 57
Sector flow rank: #5 of 13

Today's overlaps

Loan balance building + outflow index

Multi-day trend, Reversal down

Cumulative flow: +₩1.1B
outflow: 1d streak

Estimated from public price, change and volume. Not actual investor net buying.

as of Oct 22

PER

24.4

PBR

2.98

Market cap

₩1.9T

Lending balance

Building

881,080 sh

KRW 0.08T

1D +1.67%5D +1.22%

New 20,504 sh, Returned 6,017 sh

Shares borrowed through securities lending that have not yet been returned. Borrowed shares are often sold afterwards, so the balance is used as a reference for pending sell pressure.

As of 2026-10-22, FSC stock lending data

Filing check

No hurdle0 to check first, 2 improvementschecked through Oct 25

This only counts facts confirmed in filings. It does not look at whether the price is cheap or expensive, and it is not a reason to buy or sell on its own.

Earnings quality

We read the latest periodic report and check whether profit matches cash, sales match receivables, and profit from the core business matches profit from elsewhere. There is no score, only the numbers that diverge beyond a threshold and why they matter.

2026 first half, consolidated statements, filed 2026-08-14

No numbers diverge beyond the threshold

No divergence does not mean the results are good.

Net profit and operating cash flow
Net profit 284억 원, operating cash flow 1,045억 원, 369% of net profit
Sales and receivables
Year on year, sales +45.4%, receivables -17.8%
Receivables 473억 원, a year earlier 575억 원
Sales and inventory
Year on year, sales +45.4%, inventory +20.4%
Inventory 1,964억 원, a year earlier 1,631억 원
Profit from outside the core business
Pretax profit 358억 원, operating profit 298억 원, non-operating result 60억 원
17% of pretax profit came from outside the core business. In the same period last year it was -65%.

Source filing: 2026 first half Report a year earlier

This only checks whether the statement numbers agree with each other. It ignores the share price and is not a reason to buy or sell on its own. See the formula

Sector moves

Of 13 covered Healthcare stocks in Korean, 12 fell; the average change was -2.68%. ST Pharm moved in the same direction at -3.23%. Estimated sector flow was outflow.

Variables to watch Drug approvals and trial results, Drug pricing policy, US interest rates, USD/KRW

Risks to check -48% below the high, the downtrend may continue, Clinical trial failure, Drug pricing pressure

Same-sector channels

Latest news

Stock page

Posts are members' opinions. Investment decisions and their consequences are your own.

Data: KRX daily bars, InverseOne quote snapshots, public news feeds, DART filings, InverseOne company research. Not a call to buy or sell.